Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell line

Investigation into efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. Studied the contribution of YHO-1701 to enhance the antitumor properties of alectinib, YHO-1701 was combined with different doses of alectinib. The combination therapy of YHO-1701 with alectinib was found to be significantly effective against H2228 xenografts under both conditions, where the tumors remained larger and almost stable throughout the experimental period with alectinib monotherapy. This indicates that YHO-1701 offers an ideal and practical combination efficacy when used in combination with alectinib. Remarkably, in contrast with monotherapies, YHO-1701 plus alectinib diminished survivin levels in tumor tissues, suggesting that the superior antitumor activity of this combination is, at least partially, attributable to this downregulation. Regarding survivin, some studies have shown its potential characteristics as a usefu..... READ ARTICLE

Scientific reports DOI: 10.1038/s41598-021-86021-8

Authors: Keisuke Taniguchi, Hiroaki Konishi, Akiko Yoshinaga, Momomi Tsugane, Hiroyuki Takahashi, Fukiko Nishisaka, Yoshiyuki Shishido, Akira Asai

Pre-ClinicalKirk SmithMarch 1, 2021STAT3 inhibitor, combination treatment